Epidermal growth factor receptor gene expression in high grade gliomas

Folia Neuropathologica

Volumn 49, Issue 1, 2011, Pages 28-38

  Larysz, Dawid ^a   Kula, Dorota ^b   Kowal, Monika ^b   Rudnik, Adam ^a   Jarza̧b, Michał ^b   Blamek, Sławomir ^b   Bierzyńska Macyszyn, Grazyna ^c   Kowalska, Małgorzata ^b   Bazowski, Piotr ^a   Jarza̧b, Barbara ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Institute of Oncology   (Poland)

^c UNIVERSITY OF SILESIA   (Poland)

Author keywords

Anaplastic astrocytoma; EGFR; Glioblastoma; Q PCR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; AMPLICON; ARTICLE; BRAIN TUMOR; CANCER GRADING; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CLASSIFICATION;

EID: 79953661507     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004; 63: 700-707. (Pubitemid 38891086)
2. Arjona D, Bello MJ, Alonso ME, Aminoso C, Isla A, De Campos JM, Sarasa JL, Gutierrez M, Villalobo A, Rey JA. Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. Neuropathol Appl Neurobiol 2005; 31: 384-394. (Pubitemid 41059859)
3. Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM,Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted the rapy in pediatric glioma cell lines. Clin Cancer Res 2009; 15: 5753-5761.
4. Bianco R, Troiani T, Tortora G, Ciardiello F. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer 2005; 12 Suppl 1: 159-171.
5. Bigner SH, Vogelstein B. Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma. Brain Pathol 1990; 1: 12-18.
6. Brat DJ, Shehata BM, Castellano-Sanchez AA, Hawkins C, Yost RB, Greco C, Mazewski C, Janss A, Ohgaki H, Perry A. Congenital glio blastoma: a clinicopathologic and genetic analysis. Brain Pathol 2007; 17: 276-281. (Pubitemid 47000636)
7. Collins VP, James CD. Gene and chromosomal alterations associated with the development of human gliomas. FASEB J 1993; 7: 926-930. (Pubitemid 23225550)
8. Collins VP. Oncogenesis and Progression in Human Gliomas. In: Brain tumor invasion. Mikkelsen T, Bjerkvig R, Laerum OD, Rosenblum ML (eds.). Wiley-Liss, New York 1998; pp. 71-85.
9. Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and antiangiogenic effects. Oncogene 1999; 18: 7514-7526. (Pubitemid 30035052)
10. Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992; 52: 1427-1433.
11. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992; 52: 674-679.
12. Fults D, Tippets RH, Thomas GA, Nakamura Y, White R. Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma. Cancer Res 1989; 49: 6572-6577. (Pubitemid 20008789)
13. Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurosurg 2005; 41: 292-299. (Pubitemid 41636332)
14. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584. (Pubitemid 23229640)
15. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11: 689-708. (Pubitemid 40065545)
16. Heimberger A, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 2005; 3: 38. doi: 10.1186/1479-5876-3-38.
17. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004; 44: 195-217. (Pubitemid 38263839)
18. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce gliomalike lesions in mice. Genes Dev 1998; 12: 3675-3685. (Pubitemid 29019648)
19. Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Dro zynska E, Grajkowska W, Perek D, Balcerska A, Klepacka T, Limon J. EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumors. Folia Neuropathol 2010; 48: 238-245.
20. James CD, He J, Carlbom E, Nordenskjold M, Cavenee WK, Collins VP. Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res 1991; 51: 1684-1688.
21. Kagawa N, Maruno M, Suzuki T, Hashiba T, Hashimoto N, Izumoto S, Yoshimine T. Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays. Brain Tumor Pathol 2006; 23: 41-47. (Pubitemid 44576310)
22. Kleihues P, Ohgaki H. Phenotype vs genotype in the evolution of Astrocytic brain tumors. Toxicol Pathol 2000; 28: 164-170. (Pubitemid 30078219)
23. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010; 9: 135.
24. Lammerng D, Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55: 3140-3148.
25. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 1994; 9: 949-954. (Pubitemid 24065936)
26. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 1984; 44: 753-760. (Pubitemid 14184614)
27. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997; 57: 5254-5257. (Pubitemid 27516358)
28. Massimino M, Buttarelli FR, Antonelli M, Gandola L, Modena P, Giangaspero F. Intracranial ependymoma: factors affecting outcome. Future Oncol 2009; 5: 207-216.
29. Meng QH, Zhou LX, Luo JL, Cao JP, Tong J, Fan SJ. Effect of 7-hydroxystaurosporine on glioblastoma cell invasion and migration. Acta Pharmacol Sin 2005; 26: 492-499. (Pubitemid 40477999)
30. Nakamura M, Shimada K, Ishida E, Higuchi T, Nakase H, Sakaki T, Konishi N. Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol 2007; 9: 113-123. (Pubitemid 46580313)
31. Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR, Harris AL. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985; 1: 366-368. (Pubitemid 15163478)
32. Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G, James CD. Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 1998; 4: 215-222. (Pubitemid 28062899)
33. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B. Overexpression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 1986; 149: 9-14. (Pubitemid 16013282)
34. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
35. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT. Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium. J Neurosurg 1990; 73: 106-112. (Pubitemid 20206391)
36. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U, Reifenberger G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 1999; 59: 6091-6096. (Pubitemid 30035626)
37. Sainsbury JR, Malcolm AJ, Appleton DR, Farndon JR, Harris AL. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 1985; 38: 1225-1228. (Pubitemid 16215034)
38. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, Kiessling M. Amplification of the epidermal-growth-factorreceptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994; 56: 72-77. (Pubitemid 24044796)
39. Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT. Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys 2005; 63: 704-710. (Pubitemid 41400055)
40. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001; 93: 1246-1256. (Pubitemid 32816199)
41. Smits A. Low-grade gliomas: clinical and pathobiological aspects. Histol Histopathol 2002; 17: 253-260. (Pubitemid 34116429)
42. Sobol RE, Astarita RW, Hofeditz C, Masui H, Fairshter R, Royston I, Mendelsohn J. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 1987; 79: 403-407. (Pubitemid 17126586)
43. Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, Suri A, Gupta D, Sarkar C. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 2009; 11: 274-280.
44. Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M. Primary glioblastoma multiforme in younger pa tients: a single-institution experience. Tumori 2006; 92: 407-411. (Pubitemid 44861776)
45. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997; 8: 1197-1206. (Pubitemid 28164074)
46. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yasargil MG, Wiest ler OD. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1993; 77: 295-301.
47. von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992; 52: 4277-4279.
48. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-223; discussion 23-24.
49. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55: 3140-3148.
50. Wolańczyk M, Hułas-Bigoszewska K, Witusik-Perkowska M, Papierz W, Jaskólski D, Liberski PP, Rieske P. Imperfect oligodendrocytic and neuronal differentiation of glioblastoma cells. Folia Neuropathol 2010; 48: 27-34.
51. Wygoda Z, Kula D, Bierzyńska-Macyszyn G, Larysz D, Jarzab M, Właszczuk P, Bazowski P, Wojtacha M, Rudnik A, Stepień T, Kaspera W, Etmańska A, Składowski K,Tarnawski R, Kokocińska D, Jarzab B. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma (Larchmt) 2006; 25: 125-132. (Pubitemid 43967697)
52. Wygoda Z, Tarnawski R, Brady L, Steplewski Z, Bazowski P, Wojtacha M, Stepien T, Kula D, Skladowski K, Kokocinska D, Wygoda A, Pawlaczek A, Etmanska A, Larysz D, Jarzab B. Simultaneous radiotherapy and radioimmunotherapy of malignant gliomas with anti-EGFR antibody labelled with iodine 125. Preliminary results. Nucl Med Rev Cent East Eur 2002; 5: 29-33. (Pubitemid 34705107)
53. Yamauchi T, Ueki K, Tobe K, Tamemoto H, Sekine N, Wada M, Honjo M, Takahashi M, Takahashi T, Hirai H, Tushima T, Akanuma Y, Fujita T, Komuro I, Yazaki Y, Kadowaki T. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature 1997; 390: 91-96. (Pubitemid 27494763)
54. Yoon KS, Lee MC, Kang SS, Kim JH, Jung S, Kim YJ, Lee JH, Ahn KY, Lee JS, Cheon JY. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma. J Korean Med Sci 2001; 16: 481-488. (Pubitemid 33741349)
55. Zawrocki A, Biernat W. Epidermal growth factor receptor in glioblastoma. Folia Neuropathol 2005; 43: 123-132. (Pubitemid 41645171)